Research and Markets Logo More The European Biosimilar Insulin Glargine & Lispro Market is projected to reach $1.9 billion by 2024, owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedentary lifestyle. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of biosimilar insulin glargine and lispro market in the forthcoming years.The insulin analogue retains its glucose lowering property for 24 hours with just one injection. Due to this property, the insulin analogue is preferred for maintaining the basal insulin level throughout the day, thereby aiding the market growth.Growing concern regarding the cost of insulin treatment is surging the demand for biosimilar insulin glargine and lispro that have the potential to reduce diabetes treatment costs, which is anticipated to boost the growth of market in the next 5 years. Moreover, ageing population and changing eating habits are further giving healthy push to the European Biosimilar Insulin Glargine and Lispro Market.On the basis of end-users, the biosimilar insulin glargine and lispro market is bifurcated into Type 1 Diabetes and Type 2 Diabetes. […] Therefore, the utilization of biosimilar insulin glargine and lispro to treat Type 2 diabetes is expected to witness some growth during the forecast period.Some of the players in the European Biosimilar Insulin Glargine & Lispro Market are Sanofi, Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk, Sandoz-Gan Lee , etc.
Click here to read the full article